<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492438</url>
  </required_header>
  <id_info>
    <org_study_id>WS2113445</org_study_id>
    <nct_id>NCT02492438</nct_id>
  </id_info>
  <brief_title>13 Valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients</brief_title>
  <official_title>Immunogenicity and Safety of the 13-valent Pneumococcal Conjugate Vaccine in Chronic Dialysis Patients That Are 23-valent Pneumococcal Polysaccharide Vaccine Naive and Pre-immunized.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AZ Sint-Jan AV</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AZ Sint-Jan AV</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine
      as compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients
      treated with chronic hemodialysis that are pre-immunized with the PPSV23 vaccine or are PPV23
      vaccine naïve by measuring the ELISA and OPA (opsonophagocytic assay) titers after 4 and 52
      weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The immunogenicity of the PCV13 (13 valent pneumococcal conjugated vaccine) vaccine as
      compared to the PPV23 (23 valent pneumococcal polysaccharide vaccine) vaccine in patients
      treated with chronic hemodialysis that are pre-immunized with the PPV23 vaccine or are PPV23
      vaccine naïve will be measured by ELISA and OPA (opsonophagocytic assay) titers after 4 and
      52 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody response after vaccination to involved serotypes measured by OPA and ELISA</measure>
    <time_frame>52 weeks after vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>record of side effects of vaccination</measure>
    <time_frame>first week after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody response after vaccination to involved serotypes measured by OPA and ELISA</measure>
    <time_frame>4 weeks after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">154</enrollment>
  <condition>Chronic Kidney Failure</condition>
  <arm_group>
    <arm_group_label>PPV23 naive, PPV23 vaccination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>vaccination with PPV-23 in 40 PPV-23 naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV23 naive, PCV13 vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccination with PCV-13 in 40 PPV-23 naive patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV23 &gt; 4 years ago, PCV13 vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccination with PCV-13 in 40 patients that received PPV-23 more than 4 years ago</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PPV23 &lt; 4 years, PCV13 vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>vaccination with PCV-13 in 40 patients that received PPV-23 less than 4 years ago</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PPV23 vaccination or PCV13 vaccination</intervention_name>
    <arm_group_label>PPV23 naive, PPV23 vaccination</arm_group_label>
    <arm_group_label>PPV23 naive, PCV13 vaccination</arm_group_label>
    <arm_group_label>PPV23 &gt; 4 years ago, PCV13 vaccination</arm_group_label>
    <arm_group_label>PPV23 &lt; 4 years, PCV13 vaccination</arm_group_label>
    <other_name>Prevenar 13</other_name>
    <other_name>Pneumovac 23</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. they are under chronic dialysis treatment

          2. are 50 years or older and not pregnant

          3. have no immediate life threatening conditions

          4. are not allergic to one of the compounds of the vaccine

          5. have a known pneumococcal vaccination status

          6. give their informed consent.

        Exclusion Criteria:

        Patients not fulfilling the inclusion criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefaan J Vandecasteele, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology and Infectious Diseases, AZ Sint-Jan Brugge, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dienst Nefrologie, OLV Ziekenhuis</name>
      <address>
        <city>Aalst</city>
        <zip>9300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge Oostende AV</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>July 5, 2015</last_update_submitted>
  <last_update_submitted_qc>July 5, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AZ Sint-Jan AV</investigator_affiliation>
    <investigator_full_name>Vandecasteele Stefaan Johan</investigator_full_name>
    <investigator_title>Stefaan Johan Vandecasteele, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>pneumococcal vaccination</keyword>
  <keyword>dialysis</keyword>
  <keyword>immune response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

